171 related articles for article (PubMed ID: 37770109)
1. [
Chan CY; Chen Z; Guibbal F; Dias G; Destro G; O'Neill E; Veal M; Lau D; Mosley M; Wilson TC; Gouverneur V; Cornelissen B
J Nucl Med; 2023 Dec; 64(12):1965-1971. PubMed ID: 37770109
[TBL] [Abstract][Full Text] [Related]
2. A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy.
Destro G; Chen Z; Chan CY; Fraser C; Dias G; Mosley M; Guibbal F; Gouverneur V; Cornelissen B
Nucl Med Biol; 2023; 116-117():108312. PubMed ID: 36621256
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer.
Hoffman SLV; Mixdorf JC; Kwon O; Johnson TR; Makvandi M; Lee H; Aluicio-Sarduy E; Barnhart TE; Jeffery JJ; Patankar MS; Engle JW; Bednarz BP; Ellison PA
Nucl Med Biol; 2023; 122-123():108368. PubMed ID: 37490805
[TBL] [Abstract][Full Text] [Related]
4. PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma.
Lee H; Riad A; Martorano P; Mansfield A; Samanta M; Batra V; Mach RH; Maris JM; Pryma DA; Makvandi M
J Nucl Med; 2020 Jun; 61(6):850-856. PubMed ID: 31676730
[TBL] [Abstract][Full Text] [Related]
5. PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.
Wilson T; Pirovano G; Xiao G; Samuels Z; Roberts S; Viray T; Guru N; Zanzonico P; Gollub M; Pillarsetty NVK; Reiner T; Bargonetti J
Mol Pharm; 2021 Sep; 18(9):3418-3428. PubMed ID: 34318678
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer.
Sreekumar S; Zhou D; Mpoy C; Schenk E; Scott J; Arbeit JM; Xu J; Rogers BE
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834491
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
8. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
9. PARP-targeted Meitner-Auger Electron-emitting Radiopharmaceutical for Radioligand Therapy.
Tan KV
Radiol Imaging Cancer; 2023 Nov; 5(6):e239022. PubMed ID: 37975803
[No Abstract] [Full Text] [Related]
10. Imaging PARP with [
Chan CY; Chen Z; Destro G; Veal M; Lau D; O'Neill E; Dias G; Mosley M; Kersemans V; Guibbal F; Gouverneur V; Cornelissen B
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3668-3678. PubMed ID: 35614267
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
13. Targeted Brain Tumor Radiotherapy Using an Auger Emitter.
Pirovano G; Jannetti SA; Carter LM; Sadique A; Kossatz S; Guru N; Demétrio De Souza França P; Maeda M; Zeglis BM; Lewis JS; Humm JL; Reiner T
Clin Cancer Res; 2020 Jun; 26(12):2871-2881. PubMed ID: 32066626
[TBL] [Abstract][Full Text] [Related]
14. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
[TBL] [Abstract][Full Text] [Related]
15. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
16. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer.
Shen CJ; Minn I; Hobbs RF; Chen Y; Josefsson A; Brummet M; Banerjee SR; Brayton CF; Mease RC; Pomper MG; Kiess AP
Theranostics; 2020; 10(7):2888-2896. PubMed ID: 32194842
[TBL] [Abstract][Full Text] [Related]
17. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
18. PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview.
Filippi L; Urso L; Evangelista L
Curr Issues Mol Biol; 2024 Mar; 46(4):3039-3049. PubMed ID: 38666920
[TBL] [Abstract][Full Text] [Related]
19. PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
Riad A; Gitto SB; Lee H; Winters HD; Martorano PM; Hsieh CJ; Xu K; Omran DK; Powell DJ; Mach RH; Makvandi M
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352773
[TBL] [Abstract][Full Text] [Related]
20. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
